There are 2789 resources available
1047P - Efficacy of checkpoint inhibitors (CPIs) in acral melanoma (AM)
Presenter: Prachi Bhave
Session: ePoster Display
1048P - Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
Presenter: Jeeyun Lee
Session: ePoster Display
1049P - Clinical models to predict response in mucosal melanoma (MM) patients (pts) treated with anti-PD-1 (PD1) or combined with ipilimumab (PD1+IPI)
Presenter: Florentia Dimitriou
Session: ePoster Display
1050P - Outcome and impact of immune related adverse events in patients with advanced melanoma treated with checkpoint inhibitors
Presenter: Arkhjamil Angeles
Session: ePoster Display
1051P - Impacts of skeletal muscle on survival in resected stage III malignant melanoma
Presenter: Susie Youn
Session: ePoster Display
1052P - Survival outcomes predicted by irAEs on 18F-FDG-PET in response to PD-1 antibody therapy in metastatic melanoma
Presenter: Sarah Lewis
Session: ePoster Display
1086P - IBI310 alone or in combination with sintilimab for advanced melanoma: Updated results of a phase Ia/Ib study
Presenter: BIN LIAN
Session: ePoster Display
1087P - The importance of anti-PD-1 dosing in the treatment of patients with inoperable or metastatic melanoma
Presenter: Bozena Cybulska-Stopa
Session: ePoster Display
1088P - Adjuvant dabrafenib plus trametinib (DT) treatment completion in patients with resected melanoma in Spain: A retrospective observational study (GEM 1901 - DESCRIBE-AD)
Presenter: Jose Luis Manzano
Session: ePoster Display
1089TiP - Efficacy and tolerability of anti-PD1 antibody in combination with pulsed hedgehog inhibitor in advanced basal cell carcinoma
Presenter: Aurelio Boerlin
Session: ePoster Display